BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 9066686)

  • 1. Anti-p53 antibodies in serum of smokers and head and neck cancer patients.
    Wollenberg B; Jan NV; Pitzke P; Reiter W; Stieber P
    Anticancer Res; 1997; 17(1A):413-8. PubMed ID: 9066686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new prognostic indicator for head and neck cancer--p53 serum antibodies?
    Gottschlich S; Folz BJ; Goeroegh T; Lippert BM; Maass JD; Werner JA
    Anticancer Res; 1999; 19(4A):2703-5. PubMed ID: 10470224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antibody formation to cellular p53 protein in patients with squamous cell carcinomas of the upper respiratory and digestive system].
    Maass JD; Gottschlich S; Lippert BM; Niemann AM; Görögh T; Werner JA
    Laryngorhinootologie; 1996 Jan; 75(1):53-6. PubMed ID: 8851121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prognostic value of antibodies against p53 in patients with oral squamous cell carcinoma--five years survival rate].
    Hofele C; Schwager-Schmitt M; Volkmann M
    Laryngorhinootologie; 2002 May; 81(5):342-5. PubMed ID: 12001023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of p53 antibody response in patients with squamous cell carcinoma of the head and neck.
    Lavieille JP; Lubin R; Soussi T; Reyt E; Brambilla C; Riva C
    Anticancer Res; 1996; 16(4C):2385-8. PubMed ID: 8816839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 autoantibodies from patients with head and neck cancer recognise common epitopes on the polypeptide chain of p53.
    Saleh J; Brunner C; Gölzer R; Nastainczyk W; Montenarh M
    Cancer Lett; 2006 Feb; 233(1):48-56. PubMed ID: 15913883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Head and neck cancer and p53-immunogenicity.
    Maass JD; Gottschlich S; Goeroegh T; Lippert BM; Werner JA
    Anticancer Res; 1997; 17(4B):2873-4. PubMed ID: 9329551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absence of p53 autoantibodies in sera from glioma patients.
    Rainov NG; Dobberstein KU; Fittkau M; Bahn H; Holzhausen HJ; Gantchev L; Burkert W
    Clin Cancer Res; 1995 Jul; 1(7):775-81. PubMed ID: 9816045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 protein, EGF receptor, and anti-p53 antibodies in serum from patients with occupationally derived lung cancer.
    Schneider J; Presek P; Braun A; Bauer P; Konietzko N; Wiesner B; Woitowitz HJ
    Br J Cancer; 1999 Aug; 80(12):1987-94. PubMed ID: 10471051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The detection of quantitative serum p53 protein in lung cancer.
    Sen E; Gönüllü U; Akar N
    Tuberk Toraks; 2005; 53(3):231-7. PubMed ID: 16258881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Divergence between the high rate of p53 mutations in skin carcinomas and the low prevalence of anti-p53 antibodies.
    Moch C; Moysan A; Lubin R; de la Salmonière P; Soufir N; Galisson F; Vilmer C; Venutolo E; Le Pelletier F; Janin A; Basset-Séguin N
    Br J Cancer; 2001 Dec; 85(12):1883-6. PubMed ID: 11747330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P53 auto-antibodies in the sera of patients with oral squamous cell carcinoma.
    Friedrich RE; Bartel-Friedrich S; Plambeck K; Bahlo M; Klapdor R
    Anticancer Res; 1997; 17(4B):3183-4. PubMed ID: 9329632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 autoantibodies as tumor marker in head and neck squamous cell cancer.
    Gottschlich S; Hoffmann M; Maass JD; Görörgh T; Buhmann V; Hoffmann-Fazel A; Rudert H; Maune S
    Anticancer Res; 2003; 23(2A):913-5. PubMed ID: 12820322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoantibodies against P53 protein in patients with transitional cell carcinoma of the bladder.
    Sanchez-Carbayo M; Chulia MT; Niveiro M; Aranda I; Mira A; Soria F
    Anticancer Res; 1999; 19(4C):3531-7. PubMed ID: 10629648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of serum autoantibodies to tumor suppressor gene p53 with a new enzyme-linked immunosorbent assay in patients with ovarian cancer.
    Marx D; Frey M; Zentgraf H; Adelssen G; Schauer A; Kuhn W; Meden H
    Cancer Detect Prev; 2001; 25(2):117-22. PubMed ID: 11341346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a population-based epidemiological study.
    Lenner P; Wiklund F; Emdin SO; Arnerlöv C; Eklund C; Hallmans G; Zentgraf H; Dillner J
    Br J Cancer; 1999 Feb; 79(5-6):927-32. PubMed ID: 10070892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prognostic significance of p53 autoantibodies in serum of patients with breast carcinoma].
    Huober J; Sprenger H; Costa SD; Zentgraf H; Schmid H; Kaufmann M; Bastert G
    Zentralbl Gynakol; 1996; 118(10):560-4. PubMed ID: 8999710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma.
    Shimada H; Takeda A; Arima M; Okazumi S; Matsubara H; Nabeya Y; Funami Y; Hayashi H; Gunji Y; Suzuki T; Kobayashi S; Ochiai T
    Cancer; 2000 Oct; 89(8):1677-83. PubMed ID: 11042560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating p53 antibodies as early markers of oral cancer: correlation with p53 alterations.
    Ralhan R; Nath N; Agarwal S; Mathur M; Wasylyk B; Shukla NK
    Clin Cancer Res; 1998 Sep; 4(9):2147-52. PubMed ID: 9748133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Serum anti-p53 antibodies in gastric cancer patients].
    Lawniczak M; Bielicki D; Sulzyc-Bielicka V; Marlicz K; Starzyńska T
    Pol Merkur Lekarski; 2007 Sep; 23(135):192-5. PubMed ID: 18080693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.